Acticor Biotech has selected Catalent’s proprietary GPEx technology for the development of its Fab candidate, ACT-017, targeting the platelet glycoprotein VI (GPVI). The GPEx platform creates stable, high-yielding mammalian cell lines with high speed and efficiency and the advantages of applying GPEx technology span from early feasibility studies, to clinical manufacturing, through to commercial scale production. To date, seven GPEx based antibody and protein products are approved and markete...